SARRP 200 Small animal radiation research platform

描述（由申请人提供）：本申请申请资金用于购买宾夕法尼亚大学动物和细胞使用的精密X-Irradiator/ConeBeam CT。该仪器（命名为小动物辐射研究平台- sarrp）代表了目前任何仪器的重大进步，由约翰霍普金斯大学的John Wong博士在NCI通过生物工程研究伙伴关系机制的支持下开发。SARRP解决了大鼠和小鼠图像引导放射治疗研究中的一个关键需求，其分辨率和准确性可与人类治疗相媲美（在比例基础上）。以前所有用于动物的仪器都源自用于人类、大型动物或工业的标准辐照器。这些都是50年前的老技术，只有微小的改进。直到这台新机器的开发（由Gulmay Medical， Inc.商业化开发和销售），用于动物辐照器的光束准直仅限于屏蔽块，并且大多数辐照器没有光束方向的自由运动。目前的仪器具有0.5 mm2的光束能力（改进了400倍），光束方向可以在1200以上变化，具有精确的等中心激光控制。照射台具有四维运动控制（X-Y-Z和旋转），允许完全灵活的剂量管理。最重要的是，该仪器被设计为在低功率下作为锥束CT （CBCT）仪器运行，并且该仪器的软件是根据人体剂量规划建模的，使用CBCT数据。仪器的软件控制也将允许与其他模式的图像融合，重要的是PET和MRI。该仪器将与其他最先进的成像设备一起使用，最初将安装在约翰摩根大楼辐射研究部门占用的空间中，随后将转移到宾夕法尼亚大学新的佩雷尔曼高级医学中心。因此，除了为放射肿瘤科提供先进的研究能力外，该仪器还将为宾夕法尼亚大学小动物成像设备的所有其他用户提供联合研究的机会。重要的是，由于该设备的精确性，正常组织研究的许多方面将成为可能。例子包括实际比较，使用x射线，为罗伯茨质子放射治疗中心设计的扫描光束系统和小鼠肺和脑的特定区域的选择性照射。

DESCRIPTION (provided by applicant): This application requests funds to purchase a precision X-Irradiator/ConeBeam CT for animal and cellular use at the University of Pennsylvania. This instrument (named Small Animal Radiation Research Platform-SARRP) represents a significant advance over any current instrument and was developed by Dr. John Wong at Johns Hopkins University, with support from the NCI through the Bioengineering Research Partnership mechanism. The SARRP addresses a critical need in Radiation Research for Image Guided Radiotherapy in rats and mice with resolution and accuracy comparable (on a scale- proportional basis) to therapy in humans. All former instruments for animal use have been derived from standard irradiators used for humans, large animals or industry. These represent, with minor improvements, 50-yr old technology. Until the development of this new machine (being commercially developed and sold by Gulmay Medical, Inc.) beam collimation for animal irradiators has been limited to shielding blocks and most irradiators had no freedom of movement for beam direction. The current instrument has the capability of 0.5 mm2 beam (a 400-fold improvement) and beam direction can be varied over 1200, with precise laser- based control of isocenter. The irradiation stage has 4-dimensional movement control (X-Y-Z and rotation) allowing complete flexibility of dose administration. Most importantly, the instrument is designed to be operated under low power as a cone- beam CT (CBCT) instrument and software for the instrument is modeled after human dose- planning, using the CBCT data. The instruments software control will also allow image fusion with other modalities, importantly PET and MRI. The instrument will be used in conjunction with other state-of-the art imaging equipment and will be initially installed in space occupied by the Radiation Research Division in the John Morgan Building and later moved to the new Perelman Center for Advanced Medicine at the University of Pennsylvania. Thus, in addition to providing advanced research capabilities for the Radiation Oncology Department, this instrument will open a world of opportunity for combined research with all other users of the Small Animal Imaging facilities at PENN. Importantly, numerous aspects of normal tissue research will become possible due to the precision of this device. Examples include realistic comparisons, using X-rays, of the scanned beam system designed for the Roberts Proton Radiotherapy center and selective irradiation of specific regions of mouse lung and brain. PUBLIC HEALTH RELEVANCE: This application requests support to purchase a unique animal irradiator, named the 'Small Animal Radiation Research Platform' (SARRP - Gulmay Medical). This instrument represents a unique, revolutionary, technical achievement that for the first time allows state-of-the art radiotherapy to be delivered to small animals (mice and rats) to closely recapitulate the parameters used for treatment of human cancer patients with radiotherapy. This will allow researchers in different fields (Radiation Oncology, Radiology, Pulmonary Medicine, etc), to study the effects of radiation on the tumor and surrounding normal tissues. This research will lead to better approaches to deliver radiation to the target, mitigate normal tissue toxicity and image changes in normal tissues before they manifest pathologically, thereby improving overall human health and quality of life.